Geron (GERN) Set to Announce Earnings on Thursday

Geron (NASDAQ:GERN) is set to announce its earnings results before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Geron (NASDAQ:GERN) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. Geron had a negative return on equity of 63.33% and a negative net margin of 77,691.14%. The firm’s revenue for the quarter was down 77.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.10) EPS. On average, analysts expect Geron to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Geron Stock Performance

Shares of GERN stock traded down $0.14 during trading hours on Tuesday, reaching $4.00. 7,302,152 shares of the company’s stock were exchanged, compared to its average volume of 11,181,813. The company has a market cap of $2.19 billion, a P/E ratio of -12.55 and a beta of 0.61. Geron has a 1 year low of $1.64 and a 1 year high of $4.30. The company’s 50 day moving average is $2.93 and its two-hundred day moving average is $2.32. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.16 and a quick ratio of 3.16.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $5.00 target price on shares of Geron in a report on Thursday, April 11th. The Goldman Sachs Group raised their price objective on Geron from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Robert W. Baird downgraded Geron from an “outperform” rating to a “neutral” rating and set a $4.50 target price on the stock. in a research report on Tuesday. TD Cowen initiated coverage on Geron in a research report on Monday. They issued a “buy” rating and a $10.00 price target for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $6.00 price objective on shares of Geron in a research report on Wednesday, April 10th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $6.10.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.